Processa Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2009-01-01
- Employees
- 13
- Market Cap
- -
- Introduction
Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. Its main product candidate is PCS499, which is intended for the treatment of Necrobiosis Lipoidica. The company was founded by David Young, Patrick Lin, Sian E. Bigora, Wendy Guy, and Chang Rung Chen on...
Processa Pharmaceuticals doses first subject in Phase II breast cancer trial
Processa Pharmaceuticals has initiated a Phase II trial of Next Generation Capecitabine (NGC-Cap) for advanced or metastatic breast cancer, aiming to compare its safety and efficacy to FDA-approved capecitabine. The trial, involving 60-90 patients across 30 global sites, seeks optimal dosing under the FDA's Project Optimus Initiative and personalized therapy potential. NGC-Cap combines PCS6422, a DPD enzyme inhibitor, with low-dose capecitabine to enhance cancer-killing effects while reducing side effects.
Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC
Processa Pharmaceuticals initiates Phase 2 trial of NGC-Cap for metastatic breast cancer, comparing it to monotherapy capecitabine. The trial aims to evaluate NGC-Cap's safety-efficacy and determine optimal dosage regimens.
© Copyright 2024. All Rights Reserved by MedPath